|Bid||6.90 x 800|
|Ask||7.55 x 800|
|Day's range||6.61 - 7.13|
|52-week range||5.80 - 25.24|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.10|
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Even if it's not a huge purchase, we think it was good to see that Georgia Erbez, the Chief Financial Officer of...